04 Hematopoietic Development and Malignancy Program

04 造血发育与恶性肿瘤项目

基本信息

批准号：
10430015
负责人：
TIMOTHY J EBERLEIN
金额：
$ 6.75万
依托单位：
WASHINGTON UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2001
资助国家：
美国
起止时间：
2001-08-02 至 2025-06-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10430015
关键词：
Acute Myelocytic Leukemia Acute T Cell Leukemia African American Area Award Basic Science CXCR4 gene Cancer Biology Cancer Center Cancer Center Support Grant Cellular biology Cellular immunotherapy Clinical Clinical Trials Clonal Evolution Collaborations Community Outreach Data Development Direct Costs Disease Dysmyelopoietic Syndromes Epigenetic Process Fellowship Female Fostering Foundations Funding Genes Genetic Genomics Goals Grant Grant Review Hematologic Neoplasms Hematopoiesis Hematopoietic Hematopoietic Neoplasms Heterogeneity Hispanic Immunology Immunotherapy International Intervention Intervention Trial Investments Journals K-Series Research Career Programs Latino Leadership Lymphoma Malignant - descriptor Malignant Neoplasms Minority Minority Participation Multiple Myeloma Mutate Myelodysplastic/Myeloproliferative Disease Myeloproliferative disease Newly Diagnosed Paper Pathway interactions Patients Peer Review Program Research Project Grants Program Reviews Publishing Recurrence Reporting Research Research Personnel Research Training Role Signal Transduction Societies Stem cell transplant Support Groups Therapeutic Intervention Training Translating Translational Research Translations United States National Institutes of Health Universities Washington base cancer cell cancer genome cancer genomics chemotherapy community engagement experience fundamental research improved indexing inhibitor therapy innovation leukemia leukemia/lymphoma leukemic stem cell medical schools medically underserved population meetings member nanotherapy next generation sequencing novel novel strategies novel therapeutics prevent programs research and development response senior faculty success therapy resistant translational goal translational potential treatment strategy tumor immunology working group

项目摘要

HEMATOPOIETIC DEVELOPMENT AND MALIGNANCY PROGRAM (HDMP): PROJECT SUMMARY The long-term goals of the Hematopoietic Development and Malignancy Program (HDMP) are to identify basic mechanisms regulating normal and malignant hematopoiesis, and develop innovative strategies to prevent, stratify, and treat hematopoietic malignancies. The HDMP has 30 members from three departments at Washington University School of Medicine. HDMP members are supported by $22.4 million direct costs in cancer-related funding, including $5.3 million direct costs from the NCI and $4.5 million direct costs from other peer-reviewed cancer-related funding. HDMP members published 760 papers during the current project period, with 20% resulting from inter-programmatic collaborations, 26% from intra-programmatic collaborations, and 30% published in journals with an impact factor ≥10. HDMP members participated in 551 clinical trials involving hematologic malignancies or stem cell transplantation, including 357 interventional trials. Basic science translation remains a top priority for the HDMP. In the current project period, 25 investigator-initiated clinical trials were developed from fundamental research performed (at least in part) at Siteman Cancer Center, including 22 investigator-initiated therapeutic interventional trials. Total interventional accruals were 2,961, of which 2,761 (93%) were interventional treatment. The interventional treatment accrual rate (as a function of reported hematologic malignancy index cases) was 38% in 2018. Working groups in leukemia, lymphoma, myeloma, and myelodysplastic syndromes/myeloproliferative neoplasms were established to develop, review, prioritize, and conduct translational research. Each working group is organized around three themes: cancer genomics, development of immunotherapies, and cancer biology. The HDMP fosters collaborative translational research and trains junior investigators through research seminars, journal clubs, work-in-progress meetings, and an annual retreat. Program leaders have identified areas of institutional strength and developed four specific translational aims. Aim 1: Leverage local expertise in cancer genomics to identify key genetic and epigenetic alterations in hematopoietic malignancies and develop their translational potential. Aim 2: Develop fundamental discoveries in immunology into novel immunotherapies targeting hematopoietic malignancies. A particular area of focus is the development of novel cellular immunotherapies for hematopoietic malignancies. Aim 3: Translate fundamental discoveries in cancer cell biology into novel strategies to treat hematopoietic malignancies and/or improve stem cell transplantation. Aim 4: Identify and develop junior investigators in hematopoietic malignancies.

造血发育和恶性肿瘤计划 (HDMP)：项目摘要造血发育和恶性肿瘤计划 (HDMP) 的长期目标是确定基本的调节正常和恶性造血的机制，并制定创新策略来预防、 HDMP 拥有来自三个科室的 30 名成员。华盛顿大学医学院的 HDMP 成员获得 2240 万美元的直接费用支持。癌症相关资金，包括 NCI 提供的 530 万美元直接费用和其他机构提供的 450 万美元直接费用 HDMP 成员在当前项目期间发表了 760 篇论文，其中 20% 来自项目间合作，26% 来自项目内合作，以及 30% 发表在影响因子≥10 的期刊上，HDMP 成员参与了 551 项临床试验。血液恶性肿瘤或干细胞移植，包括 357 项介入基础科学试验。翻译仍然是 HDMP 的首要任务。在当前项目期间，有 25 项研究者发起的临床试验。根据 Siteman 癌症中心（至少部分）进行的基础研究开发而成，其中包括 22 研究者发起的治疗性干预试验总数为 2,961 项，其中 2,761 项。 (93%) 接受介入治疗。血液系统恶性肿瘤指数病例）在 2018 年为 38%。白血病、淋巴瘤、骨髓瘤和骨髓增生异常综合征/骨髓增生性肿瘤的建立是为了开发、审查、优先排序和每个工作组都围绕三个主题组织：癌症基因组学、 HDMP 促进了合作转化研究。并通过研究研讨会、期刊俱乐部、正在进行的工作会议和培训初级研究人员年度计划领导人确定了机构优势领域并制定了四项具体务虚会。转化目标。目标 1：利用当地癌症基因组学方面的专业知识来识别关键的遗传和表观遗传改变造血系统恶性肿瘤并开发其转化潜力。目标 2：将免疫学的基本发现开发成针对目标的新型免疫疗法造血系统恶性肿瘤的一个特别关注领域是新型细胞免疫疗法的开发。用于造血系统恶性肿瘤。目标 3：将癌细胞生物学的基本发现转化为新的治疗策略造血系统恶性肿瘤和/或改善干细胞移植。目标 4：识别和培养造血系统恶性肿瘤的初级研究者。